KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.Diabetes Obes MetabPMID 34463425PMC92920572021-Dec0.98未发现恶性肿瘤人群证据。待处理
Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).Int J Clin OncolPMID 34463869无 PMCID2021-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.Lancet Respir MedPMID 34480861PMC84090662021-Dec0.98未发现恶性肿瘤人群证据。待处理
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016).Eur Urol OncolPMID 34489210PMC86741462021-Dec0.90The study is a randomized Phase III trial of radiotherapy schedules (non-drug intervention) for prostate cancer with a primary quality-of-life endpoint (bowel bother). It does not have a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, RFS, TTP, Kaplan-Meier, HR) as required.待处理
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.Future OncolPMID 34521277无 PMCID2021-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A multicenter study to evaluate the pharmacokinetics and safety of liposomal bupivacaine for postsurgical analgesia in pediatric patients aged 6 to less than 17 years (PLAY).J Clin AnesthPMID 34534923无 PMCID2021-Dec0.98未发现恶性肿瘤人群证据。待处理
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.Cancer SciPMID 34543477PMC86457052021-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.Am J PsychiatryPMID 34551584无 PMCID2021-Dec0.98未发现恶性肿瘤人群证据。待处理
Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial.Mol Cancer TherPMID 34552008无 PMCID2021-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The cross-sectional association of cognition with diabetic peripheral and autonomic neuropathy-The GRADE study.J Diabetes ComplicationsPMID 34556408PMC86087392021-Dec0.98未发现恶性肿瘤人群证据。待处理
Capacity Building for Primary Stroke Prevention Teams in Children Living With Sickle Cell Anemia in Africa.Pediatr NeurolPMID 34563875PMC85592572021-Dec0.98未发现恶性肿瘤人群证据。待处理
The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study.Inflamm ResPMID 34586459PMC84797132021-Dec0.98未发现恶性肿瘤人群证据。待处理
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.Int J Gynecol CancerPMID 34593565PMC86668152021-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.Clin Genitourin CancerPMID 34602349无 PMCID2021-Dec0.95The record meets criteria for oncology, human, randomized, Phase III, and drug intervention, but it is excluded because it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The study reports on pathological response rates and renal function, which are not time-to-event outcomes.待处理
Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study.BreastPMID 34624757PMC85036622021-Dec0.95The study is an oncology, human, randomized, Phase 2/3 trial with a drug-containing intervention and reports original results. However, the primary and reported efficacy endpoints are objective response rate (BOR) and disease control rate (DCR), which are categorical outcomes. There is no mention of survival endpoints (OS, PFS, DFS, etc.), Kaplan-Meier survival curves, or hazard ratios in the provided abstract. Therefore, it lacks the required time-to-event efficacy endpoint for inclusion in this KM-digitization cohort.待处理
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.Lancet Gastroenterol HepatolPMID 34626550无 PMCID2021-Dec0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。待处理
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.Ann OncolPMID 34656740无 PMCID2021-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.Lancet Respir MedPMID 34672949PMC85231162021-Dec0.98未发现恶性肿瘤人群证据。待处理
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet OncolPMID 34715071无 PMCID2021-Dec0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.Leuk ResPMID 34773794PMC86433222021-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lancet OncolPMID 34793718无 PMCID2021-Dec0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。待处理
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.Lancet NeurolPMID 34800398无 PMCID2021-Dec0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.Lancet NeurolPMID 34800400无 PMCID2021-Dec0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study.Lancet NeurolPMID 34800417无 PMCID2021-Dec0.98未发现恶性肿瘤人群证据。待处理
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.NaturePMID 34912120PMC89594702021-Dec0.45Primary efficacy endpoint is objective response rate (ORR), not a time-to-event endpoint. Study is eligible otherwise but requires a primary/key secondary time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP, or HR from KM) for inclusion. The time-to-event criterion cannot be established from the provided text.待处理
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.Lancet Healthy LongevPMID 36098037无 PMCID2021-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.CirculationPMID 34706555PMC86145672021-Nov-300.98未发现恶性肿瘤人群证据。待处理
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.LancetPMID 34767764无 PMCID2021-Nov-270.98未发现恶性肿瘤人群证据。待处理
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.BloodPMID 34407542PMC97284052021-Nov-250.90Eligibility requires a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, or KM/HR analysis). This study's primary endpoint is the major molecular response (MMR) rate at week 24, which is a categorical response endpoint, not a time-to-event endpoint. Therefore, it does not meet the inclusion criteria.待处理
[Chronic radiation-induced rectal injury after adjuvant radiotherapy for pelvic malignant tumors: report based on a phase 3 randomized clinical trial].Zhonghua Wei Chang Wai Ke Za ZhiPMID 34823296无 PMCID2021-Nov-250.85This is a secondary analysis from a Phase III RCT focusing on quality of life and chronic radiation-induced rectal injury as adverse events, not on survival or progression outcomes relevant to Kaplan-Meier digitization.待处理
A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-alpha) vs. Eprex® in patients with anaemia of chronic renal failure.BMC NephrolPMID 34823497PMC86209662021-Nov-250.98未发现恶性肿瘤人群证据。待处理
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).J Clin OncolPMID 34473544PMC86012792021-Nov-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.J Clin OncolPMID 34506246无 PMCID2021-Nov-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.J Clin OncolPMID 34516759PMC86013092021-Nov-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring.J Clin OncolPMID 34538072PMC86013212021-Nov-200.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 Trial.J Clin Endocrinol MetabPMID 34228102无 PMCID2021-Nov-190.98未发现恶性肿瘤人群证据。待处理
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.N Engl J MedPMID 34706189无 PMCID2021-Nov-180.98未发现恶性肿瘤人群证据。待处理
Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study.Ocul Immunol InflammPMID 32501774无 PMCID2021-Nov-170.98未发现恶性肿瘤人群证据。待处理
A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old.VaccinePMID 34706841无 PMCID2021-Nov-160.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study.Gut LiverPMID 33827990PMC85934952021-Nov-150.98未发现恶性肿瘤人群证据。待处理
Three-year outcomes of the randomized phase III SEIPLUS trial of extensive intraoperative peritoneal lavage for locally advanced gastric cancer.Nat CommunPMID 34782599PMC85944302021-Nov-150.93干预为非药物单独策略,未满足药物干预要求。待处理
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.N Engl J MedPMID 34534429无 PMCID2021-Nov-110.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.J Clin OncolPMID 34406870PMC85776822021-Nov-100.95Eligible oncology human randomized Phase III trial with time-to-event endpoint, but excluded because the primary randomized intervention (radiation therapy vs. observation) is not drug-containing. Optional tamoxifen use is not the primary drug intervention of the trial.待处理
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.J Clin OncolPMID 34436928PMC85776842021-Nov-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.J Clin OncolPMID 34520219无 PMCID2021-Nov-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study.BMC Public HealthPMID 34749675PMC85769842021-Nov-080.98未发现恶性肿瘤人群证据。待处理
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.N Engl J MedPMID 34551225PMC84828102021-Nov-040.98未发现恶性肿瘤人群证据。待处理
Cardiopulmonary-related patient-reported outcomes in a randomized clinical trial of radiation therapy for breast cancer.BMC CancerPMID 34736429PMC85699572021-Nov-040.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines divergent populations in two phase III randomized trials.Rheumatology (Oxford)PMID 33580248PMC87835382021-Nov-030.98未发现恶性肿瘤人群证据。待处理
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study).Rheumatology (Oxford)PMID 33738492PMC85662512021-Nov-030.98未发现恶性肿瘤人群证据。待处理